Rznomics Inc. Secures Australian Clinical Trial Notification for RHO-targeted Splicing Ribozyme-based RNA Editing Therapy for Retinitis Pigmentosa

SEONGNAM, South Korea, July 15, 2024 /PRNewswire/ — Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, announced that it has received Clinical Trial Notification (CTN) from the Australian Therapeutic Goods…